Clinical trials: Induction Chemotherapy
Acute Myeloid Leukemia
Testing Oral Decitabine and Cedazuridine (ASTX727) in Combination With Venetoclax for Higher-Risk Acute Myeloid Leukemia Patients
This phase Ib/II trial studies the effects of ASTX727 (decitabine and cedazuridine) in combination with venetoclax in treating patients with higher-risk acute myeloid leukemia patients who do not have a change in the gene called…
- Trial name
- NCT04817241
- Testing
- Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Cytarabine
- Where
- 7 sites in United States
- Volunteers
- 5 people
- Sponsor
- National Cancer Institute (NCI)
Alcohol Abuse, Alcohol Dependence
Ondansetron, Alcohol Use, and Alcohol-Related Symptoms In HIV+ Persons
The proposed randomized clinical trial will investigate a novel pharmacotherapy for hazardous drinking, HIV-infected men and women, using the serotonin receptor (5-HT3) antagonist ondansetron.
- Trial name
- NCT01254877
- Testing
- ondansetron
- Where
- United States
- Volunteers
- 357 people
- Sponsor
- Johns Hopkins University
Breast Cancer, Peripheral Neuropathy, Secondary to Drugs or Chemicals
Chemotherapy Induced Peripheral Neuropathy. Could Physical Therapy Help Treat Symptoms?
The cause of Chemotherapy-Induced Peripheral Neuropathy (CIPN) is still unknown. An estimated 55-60% of patients will experience lasting symptoms affecting function for years post-treatment.
- Trial name
- NCT02239601
- Testing
- Physical Therapy
- Where
- Canada
- Volunteers
- 61 people
- Sponsor
- CancerCare Manitoba
Male Breast Cancer, Nausea and Vomiting
Dexamethasone and Ondansetron Hydrochloride or Palonosetron Hydrochloride in Preventing Nausea and Vomiting in Patients Receiving Doxorubicin Hydrochloride and Cyclophosphamide For Early Stage Breast Cancer
RATIONALE: Antiemetic drugs, such as dexamethasone, ondansetron hydrochloride, and palonosetron hydrochloride, may help lessen or prevent nausea and vomiting caused by chemotherapy.
- Conditions
- Male Breast Cancer, Nausea and Vomiting, Stage I Breast Cancer, Stage II Breast Cancer
- Trial name
- NCT00343863
- Testing
- palonosetron hydrochloride, cyclophosphamide, dexamethasone
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- University of Washington
HIV, Alcoholism
Will Having Alcohol Treatment Improve Functioning?
The purpose of the study is to find out if a medication,naltrexone is helpful for HIV-infected women who sometimes drink too much.
- Trial name
- WHAT-IF (NCT01245647)
- Testing
- Naltrexone, 50mg, once per day for 4 months, Sugar pill, 50mg, once per day for 4 months
- Where
- 3 sites in United States
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- University of Florida
Chemotherapy-induced Peripheral Neuropathy
A New Method for Identifying Sensory Changes in Painful Chemotherapy-induced Peripheral Neuropathy (CIPN)
The investigators propose that using the Diode Laser fiber type Selective Stimulator (DLss) in patients with chemotherapy-induced peripheral neuropathy (CIPN) will allow for the assessment of changes in small-fiber pain…
- Trial name
- NCT03687970
- Testing
- Brief Pain Inventory, Hospital Anxiety and Depression Scale, Neuropathic Pain Symptom Inventory
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Washington University School of Medicine
Ann Arbor Stage I Hodgkin Lymphoma, Ann Arbor Stage IA Hodgkin Lymphoma
Doxorubicin, Vinblastine, Dacarbazine, Brentuximab Vedotin, and Nivolumab in Treating Patients With Stage I-II Hodgkin Lymphoma
This phase II trial evaluates how well AVD (doxorubicin, vinblastine, dacarbazine) in combination with brentuximab vedotin and nivolumab work in treating patients with stage I-II Hodgkin lymphoma.
- Conditions
- Ann Arbor Stage I Hodgkin Lymphoma, Ann Arbor Stage IA Hodgkin Lymphoma, Ann Arbor Stage IB Hodgkin Lymphoma, Ann Arbor Stage II Hodgkin Lymphoma
- Trial name
- NCT03233347
- Testing
- Brentuximab Vedotin, Dacarbazine, Doxorubicin
- Where
- 9 sites in United States
- Volunteers
- 83 people
- Sponsor
- Academic and Community Cancer Research United
Chemotherapy Induced Anemia
Study of Sotatercept for the Treatment of Chemotherapy Induced Anemia in Patients With Metastatic Breast Cancer (MK-7962-012)
The purpose of this study is to evaluate the percentage of participants in each sotatercept dose regimen who achieve a hematopoietic response during the treatment period including up to 2 months after the last dose of sotatercept…
- Trial name
- NCT00931606
- Testing
- Sotatercept
- Where
- 35 sites in United States, Russia
- Volunteers
- 30 people
- Sponsor
- Merck Sharp & Dohme LLC
Head and Neck Cancer
Study in Locally Advanced Squamous Cell Carcinoma of Head and Neck
Primary Compare response rates (relative change in tumor size) to induction chemotherapy consisting of cisplatin/paclitaxel/cetuximab +/- everolimus.
- Trial name
- NCT01133678
- Testing
- Everolimus
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- University of Chicago
Chemotherapy-induced Diarrhea
Evaluation of Octreotide LAR in Prevention of Chemotherapy-induced Diarrhea
This study will evaluate the efficacy of Octreotide LAR in preventing chemotherapy-induced diarrhea (with regimens that contain 5 fluorouracil, irinotecan and capecitabine)in patients with colorectal cancer.
- Trial name
- LARCID (NCT00582426)
- Testing
- Octreotide Long Acting Release, Standard Treatment
- Where
- 11 sites in Brazil
- Volunteers
- 139 people
- Sponsor
- Novartis Pharmaceuticals
Acute Myeloid Leukemia
Aprepitant as Antiemetic Prophylaxis in Patients With Acute Myeloid Leukemia Undergoing Induction Chemotherapy
Chemotherapy induced nausea and vomiting (CINV) is a major adverse effect of chemotherapy. This study is determining the incidence of vomiting/retching of the standard induction chemotherapy regimen for patients with acute…
- Trial name
- NCT01334086
- Testing
- Aprepitant
- Where
- Canada
- Volunteers
- 41 people
- Sponsor
- University Health Network, Toronto
Thrombocytopenia
American Trial Using Tranexamic Acid in Thrombocytopenia
The purpose of this study is to evaluate the usefulness of antifibrinolytic therapy with tranexamic acid (TXA) in preventing bleeding in patients who are thrombocytopenic due to primary bone marrow disorders or chemotherapy…
- Trial name
- A-TREAT (NCT02578901)
- Testing
- Tranexamic Acid
- Where
- 3 sites in United States
- Volunteers
- 330 people
- Sponsor
- University of Washington
Adenocarcinoma of the Pancreas, Stage IA Pancreatic Cancer
Perioperative Therapy for Resectable Pancreatic Cancer
This phase II trial studies how well giving combination chemotherapy together with intensity-modulated radiation therapy (IMRT) and surgery works in treating patients with localized pancreatic cancer that can be removed by…
- Conditions
- Adenocarcinoma of the Pancreas, Stage IA Pancreatic Cancer, Stage IB Pancreatic Cancer, Stage IIA Pancreatic Cancer
- Trial name
- NCT00609336
- Testing
- gemcitabine hydrochloride, docetaxel, capecitabine
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- University of Washington
Chemo Brain, Chemotherapy-related Cognitive Impairment
Nicotinic Treatment of Post-Chemotherapy Subjective Cognitive Impairment: A Pilot Study
The purpose of this study is to evaluate the use of a nicotine patch as a treatment for problems with attention, learning and memory in breast cancer patients who are 1-5 years post chemotherapy.
- Conditions
- Chemo Brain, Chemotherapy-related Cognitive Impairment, Chemo Fog, Breast Cancer
- Trial name
- NCT02312934
- Testing
- Transdermal nicotine
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Vanderbilt University Medical Center
Biliary Cancer
Pembrolizumab and GM-CSF in Biliary Cancer
This is an open label phase II trial to examine efficacy and safety of a novel combination of pembrolizumab plus induction GM-CSF in patients with advanced biliary cancers treated at University of California, San Francisco…
- Trial name
- NCT02703714
- Testing
- Pembrolizumab, Sargramostim
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Robin Kate Kelley
Colorectal Cancer, Chemotherapy-induced Peripheral Neuropathy
Preventive Treatment of OxaLiplatin Induced peripherAl neuRopathy in Adjuvant Colorectal Cancer
This study is to evaluate PledOx for prevention of chronic chemotherapy induced peripheral neuropathy induced by oxaliplatin in patients with Stage III or high-risk Stage II colorectal cancer (CRC).
- Trial name
- POLAR-A (NCT04034355)
- Testing
- Calmangafodipir (5 µmol/kg)
- Where
- 65 sites in Belgium, Czechia and 8 more
- Volunteers
- 301 people
- Sponsor
- Egetis Therapeutics AB (publ)
Anemia, Non-Myeloid Malignancies
Darbepoetin Alfa With or Without Intravenous (IV) Iron
To deterime the efficacy of 500 μg and 300 μg darbepoetin alfa administered subcutaneously (SC) on an every 3 weeks (Q3W) schedule, and the effect of intravenous (IV) iron supplementation in the treatment of anemia in patients…
- Trial name
- NCT00401544
- Testing
- darbepoetin alfa, IV iron dextran
- Volunteers
- 243 people
- Sponsor
- Amgen
Acute Myeloid Leukemia
Clofarabine, Idarubicin, and Cytarabine Combination in Acute Myeloid Leukemia (AML) Induction
The goal of this clinical research study is to learn if the combination of clofarabine, cytarabine, and idarubicin can help to control Acute Myeloid Leukemia (AML) in patients who are between the ages of 18 and 60 years old.
- Trial name
- NCT01025154
- Testing
- Clofarabine, Idarubicin, Cytarabine
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- M.D. Anderson Cancer Center
Breast Cancer, Colon Cancer
Topical Menthol for the Treatment of Chemotherapy Induced Peripheral Neuropathy
Primary Objective: To assess whether six-week treatment with twice daily topical Menthol application will decrease neuropathic pain as measured by the change in Brief Pain Inventory-Short Form (BPI-SF worst pain score), following…
- Conditions
- Breast Cancer, Colon Cancer, Neuropathy
- Trial name
- NCT01855607
- Testing
- topical menthol
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Columbia University
Breast Cancer, Breast Neoplasms
Pembrolizumab, IRX-2, and Chemotherapy in Triple Negative Breast Cancer
This is a Phase II, randomized, open-label trial to evaluate the clinical and immunologic activity of pembrolizumab plus chemotherapy when combined with various immunotherapy induction regimens as neoadjuvant therapy for triple…
- Trial name
- NCT04373031
- Testing
- Pembrolizumab, IRX 2
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Providence Health & Services